A. Durak Et Al. , "Glucagon-like peptide-1 receptor agonist treatment of high carbohydrate intake-induced metabolic syndrome provides pleiotropic effects on cardiac dysfunction through alleviations in electrical and intracellular Ca2+ abnormalities and mitochondrial dysfunction," CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY , vol.49, pp.46-59, 2022
Durak, A. Et Al. 2022. Glucagon-like peptide-1 receptor agonist treatment of high carbohydrate intake-induced metabolic syndrome provides pleiotropic effects on cardiac dysfunction through alleviations in electrical and intracellular Ca2+ abnormalities and mitochondrial dysfunction. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY , vol.49 , 46-59.
Durak, A., Akkuş, E., Gökçay Canpolat, A., Tuncay, E., Çorapçıoğlu, D., & Turan, B., (2022). Glucagon-like peptide-1 receptor agonist treatment of high carbohydrate intake-induced metabolic syndrome provides pleiotropic effects on cardiac dysfunction through alleviations in electrical and intracellular Ca2+ abnormalities and mitochondrial dysfunction. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY , vol.49, 46-59.
Durak, AYŞEGÜL Et Al. "Glucagon-like peptide-1 receptor agonist treatment of high carbohydrate intake-induced metabolic syndrome provides pleiotropic effects on cardiac dysfunction through alleviations in electrical and intracellular Ca2+ abnormalities and mitochondrial dysfunction," CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY , vol.49, 46-59, 2022
Durak, AYŞEGÜL Et Al. "Glucagon-like peptide-1 receptor agonist treatment of high carbohydrate intake-induced metabolic syndrome provides pleiotropic effects on cardiac dysfunction through alleviations in electrical and intracellular Ca2+ abnormalities and mitochondrial dysfunction." CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY , vol.49, pp.46-59, 2022
Durak, A. Et Al. (2022) . "Glucagon-like peptide-1 receptor agonist treatment of high carbohydrate intake-induced metabolic syndrome provides pleiotropic effects on cardiac dysfunction through alleviations in electrical and intracellular Ca2+ abnormalities and mitochondrial dysfunction." CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY , vol.49, pp.46-59.
@article{article, author={AYŞEGÜL DURAK Et Al. }, title={Glucagon-like peptide-1 receptor agonist treatment of high carbohydrate intake-induced metabolic syndrome provides pleiotropic effects on cardiac dysfunction through alleviations in electrical and intracellular Ca2+ abnormalities and mitochondrial dysfunction}, journal={CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY}, year=2022, pages={46-59} }